Archives
Please, enter cell line, author or any other phrase or word you would like to search for.
Webinars in Chinese! – Everything you need to know about HoloMonitor
To help our customers who speak different languages, PHI and our local partner in China, Bio-Sun, held two webinars in Chinese to explain everything you need to know about HoloMonitor.
HoloMonitor User Spotlight: Francesco Pasqualini
Francesco Pasqualini, Associate Professor at University Pavia, tells how he applies HoloMonitor to see how ECM affects cells over a long time.
Year-end Report 2021/22
Sales more than doubled in 2021/22, compared to previous financial year.
Synthetic antibody patent awarded to PHI by Japan
PHI announces today that the Company has been granted a patent concerning synthetic antibodies in Japan.
HoloMonitor user spotlight: Robert Judson-Torres
To be a mole or to be a melanoma? Dr. Robert Judson-Torres, Assistant Professor at Huntsman Cancer Institute, University of Utah, speaks about how HoloMonitor data has been key in his recent work.
HoloMonitor user spotlight: Frida Berlin
Frida Berlin, Ph.D. student at Lund University talks about the effect of mast cell mediators on cell behavior in respiratory disease — and the role of HoloMonitor in her research.
Keep your Flow!
This webinar covers how to set up microfluidic assays to gain the most information from a single experiment.
PHI Enters Biomanufacturing Partnership with Wake Forest Institute for Regenerative Medicine
PHI and Wake Forest Institute for Regenerative Medicine recently signed a letter of intent outlining a biomanufacturing initiative to make indispensable imaging techniques available for regenerative medicine and large-scale production of cell therapies and organs.
PHI Signs Subscription Commitments with Board Members, CEO and Owners
Subscription commitments corresponding to approximately 4 % of the initial rights issue (2.9 million SEK) have been signed with members of the company’s board, the company’s CEO and with owners.
BioStock: PHIs CEO eyes new business opportunities
BioStock contacted CEO Peter Egelberg to find out more about the rights issue of just over 72 million SEK that is currently underway, and his vision for the future.